| 101 |
NCT01291576 |
Active, not recruiting |
Functional Outcomes of Surgical Management of Deep Endometriosis Infiltrating the Rectum |
|
- Procedure: Rectal/colorectal segmental resection
- Procedure: Rectal nodule excision
|
Interventional |
Not Applicable |
- University Hospital, Rouen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of women experiencing a postoperative digestive or urinary dysfunction
- Percentage of women experiencing postoperative pain related to endometriosis
- Biberoglu & Behrman score
- (and 6 more...)
|
60 |
Female |
18 Years to 45 Years (Adult) |
NCT01291576 |
2009/069/HP |
ENDORE |
March 2011 |
September 2013 |
September 2023 |
February 8, 2011 |
June 14, 2017 |
|
- Service de Gynécologie et Obstétrique, CHU Jean de Flandre
Lille, France - Service de Gynécologique-Obstétricale et Reproduction Humaine, Hôpital Tenon, Université Pierre et Marie Curie Paris 6
Paris, France - Rouen University Hospital
Rouen, France
|
| 102 |
NCT00194233 |
Completed |
Serum and Peritoneal Fluid Bank for Endometriosis Markers |
|
|
Observational |
|
- University of Pennsylvania
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
300 |
Female |
18 Years to 50 Years (Adult) |
NCT00194233 |
708870
RRU008 |
|
November 2003 |
January 2007 |
June 2008 |
September 19, 2005 |
August 16, 2016 |
|
- University of Pennsylvania Reproductive Research Unit
Philadelphia, Pennsylvania, United States
|
| 103 |
NCT03126747 |
Recruiting |
Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea |
- Endometriosis and Dysmenorrhea
|
- Drug: BAY86-5300_YAZ-Flex
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of treatment emergent adverse events (TEAEs) and adverse drug reactions (ADRs)
- Change in periodic blood loss
- Change from baseline of compliance status in the new flexible regimen
- (and 5 more...)
|
600 |
Female |
Child, Adult, Senior |
NCT03126747 |
18703 |
|
June 29, 2017 |
June 30, 2020 |
December 30, 2020 |
April 24, 2017 |
April 17, 2018 |
|
- Many locations
Multiple Locations, Japan
|
| 104 |
NCT01412138 |
Unknown † |
Somatic Stem Cells in Endometriosis |
|
|
Observational |
|
|
Industry |
- Time Perspective: Prospective
|
- Characterization of endometrial stem cells through Flow Citometry and Side Population techniques and In vitro culture cellular proliferation to then characterize the cell population through molecular and cellular techniques.
|
30 |
Female |
20 Years to 40 Years (Adult) |
NCT01412138 |
1006-C-073-CS-F |
|
March 2011 |
April 2016 |
April 2016 |
August 9, 2011 |
April 22, 2015 |
|
- IVI Valencia
Valencia, Spain
|
| 105 |
NCT02636400 |
Active, not recruiting |
Immediate Intra Uterine Isemination (IUI) Versus Expectant Management in Postoperative Endometriosis Patients |
|
- Other: controlled ovarian stimulation with gonadotropins + intrauterine insemination
|
Interventional |
Not Applicable |
- Universitaire Ziekenhuizen Leuven
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- cumulative clinical pregnancy rate
|
24 |
Female |
18 Years to 37 Years (Adult) |
NCT02636400 |
S55983 |
|
February 2014 |
June 2017 |
December 2018 |
December 21, 2015 |
October 26, 2017 |
|
|
| 106 |
NCT03204331 |
Recruiting |
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain |
- Endometriosis Related Pain
|
- Drug: Relugolix
- Drug: Relugolix Placebo
- Drug: Low-dose Hormonal Add-back
- Drug: Low-dose Hormonal Add-back Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of responders based on daily assessment of dysmenorrhea
- Proportion of responders based on daily assessment of nonmenstrual pelvic pain
- Change from Baseline in the Endometriosis Health Profile (EHP)-30 Pain Domain Group
|
600 |
Female |
18 Years to 50 Years (Adult) |
NCT03204331 |
MVT-601-3102 |
|
August 30, 2017 |
December 2019 |
June 2020 |
July 2, 2017 |
April 3, 2018 |
|
- Andalusia
Andalusia, Alabama, United States - Aventura
Aventura, Florida, United States - Brandon
Brandon, Florida, United States - (and 64 more...)
|
| 107 |
NCT03204318 |
Recruiting |
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain |
- Endometriosis Related Pain
|
- Drug: Relugolix
- Drug: Relugolix Placebo
- Drug: Low-dose Hormonal Add-back
- Drug: Low-dose Hormonal Add-back Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Proportion of responders based on daily assessment of dysmenorrhea
- Proportion of responders based on daily assessment of nonmenstrual pelvic pain
- Change from Baseline in the Endometriosis Health Profile (EHP)-30 Pain Domain Group
|
600 |
Female |
18 Years to 50 Years (Adult) |
NCT03204318 |
MVT-601-3101 |
|
June 27, 2017 |
December 2019 |
June 2020 |
July 2, 2017 |
February 26, 2018 |
|
- Mesa
Mesa, Arizona, United States - Little Rock
Little Rock, Arkansas, United States - Anaheim
Anaheim, California, United States - (and 53 more...)
|
| 108 |
NCT01973816 |
Recruiting |
MEdical Versus SUrgical Treatments of Rectal Endometriosis |
|
- Drug: Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;
- Procedure: rectal shaving; rectal disc excision; colorectal resection
- Drug: Cyproterone acetate 50 mg; estradiol 0.5% percutaneous
- Drug: Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
|
Interventional |
Phase 3 |
- University Hospital, Rouen
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Postoperative digestive function
- Unfavorable digestive functional outcome
|
78 |
Female |
35 Years to 50 Years (Adult) |
NCT01973816 |
2013/001/HP |
MESURE |
November 2014 |
March 2018 |
November 2019 |
November 1, 2013 |
June 14, 2017 |
|
- CHU d'AMIENS
Amiens, France - Service de Gynécologie, Obstétrique et Médecine de la Reproduction CHU de CLERMONT-FERRAND Hôpital ESTAING 1 place Lucie Aubrac
Clermont-ferrand, France - CHU de DIJON
Dijon, France - (and 8 more...)
|
| 109 |
NCT03305120 |
Completed |
Musculo-scrawny Manifestation Associated With the Endometriosis |
|
- Other: pain VAS evaluation
|
Observational |
|
- Groupe Hospitalier Paris Saint Joseph
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- VAS of musculo-scrawny pain
|
41 |
Female |
18 Years to 45 Years (Adult) |
NCT03305120 |
ENDOMETRI-OS |
|
September 16, 2016 |
October 16, 2016 |
December 31, 2016 |
October 9, 2017 |
October 9, 2017 |
|
- Groupe Hospitalier Paris Saint Joseph
Paris, Ile-de-France, France
|
| 110 |
NCT01620528 |
Completed |
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain |
|
- Drug: Elagolix
- Other: placebo
|
Interventional |
Phase 3 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of responders based on daily assessment of dysmenorrhea (DYS)
- Proportion of responders based on daily assessment of non-menstrual pelvic pain (NMPP)
- Change from baseline to each month in numeric rating scale (NRS) scores
- (and 22 more...)
|
872 |
Female |
18 Years to 49 Years (Adult) |
NCT01620528 |
M12-665 |
|
May 2012 |
November 2014 |
September 2015 |
June 15, 2012 |
March 21, 2017 |
|
- Alabama Clinical Therapeutics, LLC /ID# 51487
Birmingham, Alabama, United States - Cullman Clinical Research /ID# 87953
Cullman, Alabama, United States - Mobile, Ob-Gyn, P.C. /ID# 64270
Mobile, Alabama, United States - (and 176 more...)
|
| 111 |
NCT02158845 |
Completed |
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis |
|
- Drug: LNG-IUS: levonorgestrel intrauterine system
- Drug: GnRHa: leuprolide
|
Interventional |
Phase 4 |
- University of Sao Paulo
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- change from baseline in d-dimer
- change from baseline in Coagulation times
- change from baseline in procoagulatory variables
- (and 3 more...)
|
44 |
Female |
18 Years to 40 Years (Adult) |
NCT02158845 |
SIU-LNG 001 |
SIU-LNG |
February 2010 |
September 2012 |
September 2012 |
June 9, 2014 |
January 21, 2015 |
|
- Hospital das Clinica de Ribeirao Preto
Ribeirão Preto, SP, Brazil
|
| 112 |
NCT03017989 |
Recruiting |
ICG-Based Fluorescence Imaging for Intra-operative Detection of Endometriosis |
|
|
Interventional |
Not Applicable |
- Maastricht University Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of detected endometriotic lesions with Near Infrared Light versus with white light
- Histological assessment of taken biopsies: assessment of localization of ICG uptake
- Time measurement
- (and 3 more...)
|
15 |
Female |
18 Years and older (Adult, Senior) |
NCT03017989 |
NL54458.068.15 |
|
January 2017 |
August 2018 |
December 2018 |
January 11, 2017 |
March 22, 2018 |
|
- Maastricht University Medical Center
Maastricht, Limburg, Netherlands
|
| 113 |
NCT01760954 |
Completed |
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain |
|
- Drug: Elagolix
- Other: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of responders at Month 6 based on daily assessment of dysmenorrhea (DYS)
- Proportion of responders at Month 6 based on daily assessment of non-menstrual pelvic pain (NMPP)
- Proportion of responders at each month for dyspareunia
- (and 12 more...)
|
506 |
Female |
18 Years to 50 Years (Adult) |
NCT01760954 |
M12-667 |
|
December 2012 |
May 2015 |
March 2016 |
January 4, 2013 |
January 5, 2018 |
|
- Site Reference ID/Investigator# 95545
Birmingham, Alabama, United States - Site Reference ID/Investigator# 98660
Cullman, Alabama, United States - Site Reference ID/Investigator# 95524
Mobile, Alabama, United States - (and 146 more...)
|
| 114 |
NCT01682642 |
Completed
Has Results |
The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis. |
|
|
Interventional |
Phase 4 |
- AZ Jan Palfijn Gent
- Onze Lieve Vrouw Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Metaphase II Cells (MII)
- Pregnancy Rate
- Good Embryo Quality
- (and 3 more...)
|
120 |
Female |
18 Years to 38 Years (Adult) |
NCT01682642 |
2012-000784-25 |
|
March 2012 |
October 2014 |
October 2014 |
September 11, 2012 |
March 20, 2015 |
March 20, 2015 |
- AZ Jan Palfijn
Gent, Oost-vlaanderen, Belgium
|
| 115 |
NCT02165917 |
Unknown † |
Study to Compare Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesion Barrier |
|
- Procedure: Excision plus hyaluronic acid gel
- Procedure: Excision only
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Pregnancy rate
- Endometriosis-associated pain
|
60 |
Female |
18 Years to 45 Years (Adult) |
NCT02165917 |
PHDW-003 |
|
May 2015 |
May 2017 |
May 2017 |
June 18, 2014 |
November 3, 2015 |
|
- Pius-Hospital, Department of Gynecology, Obstetrics and Gynecological Oncology, Carl von Ossietzky University
Oldenburg, Lower Saxony, Germany
|
| 116 |
NCT03232281 |
Recruiting |
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis |
|
- Drug: Triptorelin Pamoate PR 3-month
- Drug: Triptorelin Acetate PR 1-month
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of subjects castrated (E2≤184 pmol/L or 50 pg/mL)
- Percentage of subjects castrated (E2≤184 pmol/L or 50 pg/mL) at Weeks 4 and 8.
- Percentage of subjects castrated (E2≤110 pmol/L or 30 pg/mL) at Weeks 4, 8 and 12.
- (and 4 more...)
|
300 |
Female |
18 Years to 45 Years (Adult) |
NCT03232281 |
D-CN-52014-220 |
|
July 28, 2017 |
February 28, 2019 |
February 28, 2019 |
July 27, 2017 |
February 27, 2018 |
|
- Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China - China-Japan Friendship Hospital
Beijing, China - Peking University First Hospital
Beijing, China - (and 22 more...)
|
| 117 |
NCT02921763 |
Active, not recruiting |
A Survey on Efficacy and Safety in Patients With Endometriosis |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in the volume of ovarian chocolate cyst (If there are two or more cysts, a total volume)
- Change over time in dysmenorrhea score (total of a dysmenorrhea severity score and a score for the use of analgesics)
- Change over time in Visual analogue scale (VAS) for dysmenorrhea
- Change in serum CA125
|
60 |
Female |
20 Years to 49 Years (Adult) |
NCT02921763 |
DUPKST16002 |
|
August 2016 |
October 2017 |
October 2017 |
October 3, 2016 |
May 25, 2017 |
|
- Mylan Investigational Site G
Tokyo, Chiyodaku, Japan - Mylan Investigational Site N
Tokyo, Chuouku, Japan - Mylan Investigational Site C
Kyoto, Fushimiku, Japan - (and 12 more...)
|
| 118 |
NCT01712763 |
Completed |
Degarelix in the Treatment of Endometriosis Recurrence |
|
- Drug: degarelix
- Drug: goserelin
|
Interventional |
Phase 3 |
- Centre for Endocrinology and Reproductive Medicine, Italy
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- disease free time
- time of disappearance pain
|
100 |
Female |
20 Years to 45 Years (Adult) |
NCT01712763 |
C06/2012 |
|
November 2012 |
March 2016 |
March 2016 |
October 24, 2012 |
April 27, 2016 |
|
|
| 119 |
NCT02511626 |
Active, not recruiting |
Quality of Life in Endometriosis - a Case Control Study |
- Endometriosis
- Quality of Life
- Pain
- (and 4 more...)
|
|
Observational |
|
- University of Zurich
- Triemli Hospital
- Cantonal Hospital of St. Gallen
- (and 7 more...)
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Quality of life i.e. pain, infertility, partnership, sexuality, depression, anxiety, stress, medical support, comorbidities and risk factors in the development of endometriosis: childhood trauma, life style factors, menstrual history
- Prevalences of diseases such as dyspareunia, sexual disorders or adverse childhood experiences in the control group.
- Comorbidity of chronic pain.
|
1267 |
Female |
18 Years and older (Adult, Senior) |
NCT02511626 |
Endo_QOL |
|
January 2010 |
December 2016 |
December 2018 |
July 30, 2015 |
November 13, 2017 |
|
- Clinic for Reproductive Endocrinology, University Hospital Zurich
Zurich, Switzerland
|
| 120 |
NCT00117481 |
Completed |
Evaluation of DR-2001 for the Management of Endometriosis-Related Pelvic Pain |
|
- Drug: DR-2001a
- Drug: DR-2001b
- Other: Placebo
|
Interventional |
Phase 2 |
- Duramed Research
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean change in nonmenstrual pelvic pain at end of treatment
- Mean change in nonmenstrual pelvic pain and endometriosis-related symptoms
- Safety and tolerability of DR-2001
|
90 |
Female |
18 Years to 45 Years (Adult) |
NCT00117481 |
DR-DZL-201 |
|
June 2005 |
December 2007 |
December 2007 |
July 7, 2005 |
May 9, 2014 |
|
- Duramed Investigational Site
Enterprise, Alabama, United States - Duramed Investigational Site
Montgomery, Alabama, United States - Duramed Investigational Site
Phoenix, Arizona, United States - (and 38 more...)
|
| 121 |
NCT03373422 |
Recruiting |
A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best |
|
- Drug: BAY1128688
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Absolute change in mean pain of the 7 days with worst EAPP comparing the 28-day baseline cycle (baseline period of daily pain recordings) to the 28-day end of treatment cycle (daily pain recordings during the last 28 days of the treatment period)
- Incidence of treatment-emergent adverse events
|
120 |
Female |
18 Years and older (Adult, Senior) |
NCT03373422 |
17472
2017-000244-18 |
AKRENDO1 |
November 30, 2017 |
March 29, 2019 |
May 10, 2019 |
December 14, 2017 |
April 9, 2018 |
|
- Kepler Universitätsklinikum
Linz, Oberösterreich, Austria - Medizinische Universität Graz
Graz, Steiermark, Austria - Landeskrankenhaus Bregenz
Bregenz, Vorarlberg, Austria - (and 88 more...)
|
| 122 |
NCT03161704 |
Recruiting |
Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol |
|
|
Observational |
|
- Yale University
- Augusta University
- Penn State University
- (and 5 more...)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Collection of up to 3 2cm samples of Endometrial Tissue
- Collection of Serum 1 will be 2 10ml serum tubes of serum
- Collection of Serum 2 will be 2 7 ml serum tubes of serum
|
500 |
Female |
18 Years to 44 Years (Adult) |
NCT03161704 |
ENDOmarker |
|
July 8, 2016 |
January 2021 |
January 2021 |
May 22, 2017 |
April 17, 2018 |
|
- Augusta University
Augusta, Georgia, United States - Wayne State University
Southfield, Michigan, United States - Pennsylvania State University
Hershey, Pennsylvania, United States - University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 123 |
NCT01334762 |
Completed |
Efficacy of Letrozole and CC Alone in an IUI Program in Cases With Surgically Treated Minimal to Mild Endometriosis |
|
- Drug: Letrozole/IUI
- Drug: CC/IUI
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical pregnancy rate per cycle
- Miscarriage rate.
|
136 |
Female |
20 Years to 36 Years (Adult) |
NCT01334762 |
MU-157x
FMH-92-B |
|
May 2007 |
June 2010 |
June 2010 |
April 13, 2011 |
April 13, 2011 |
|
- Mansoura University Hospitals,OB/GYN department
Mansoura, Dakahlia Governorate, Egypt
|
| 124 |
NCT00370123 |
Withdrawn |
The Immune Base of Endometriosis |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
50 |
Female |
18 Years to 45 Years (Adult) |
NCT00370123 |
SHEBA-06-4251-RM-CTIL |
|
September 2006 |
|
|
August 30, 2006 |
June 28, 2011 |
|
|
| 125 |
NCT01767090 |
Completed |
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain |
|
- Drug: ASP1707
- Drug: Placebo
- Drug: Leuprorelin acetate
|
Interventional |
Phase 2 |
- Astellas Pharma Europe B.V.
- Astellas Pharma Inc
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to the end of 12 weeks treatment of pain score for overall pelvic pain
- Change from baseline to the end of 12 weeks treatment of pain score for dysmenorrhea
- Change from baseline to the end of 12 weeks treatment of pain score for non-menstrual pelvic pain
- (and 16 more...)
|
912 |
Female |
18 Years to 45 Years (Adult) |
NCT01767090 |
1707-CL-0011
2012-002791-14 |
|
December 2012 |
May 2015 |
July 2015 |
January 14, 2013 |
August 13, 2015 |
|
- Site: 1006
Bruxelles, Belgium - Site: 1002
Genk, Belgium - Site: 1003
Gent, Belgium - (and 82 more...)
|
| 126 |
NCT01595724 |
Completed |
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life |
|
- Drug: Visanne (Dienogest, BAY86-5258)
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of patients, who show an improvement of the EHP-5 items
- Mean changes of EHP-5 items by using scores for pre-defined categories
- Baseline demographic characteristics and disease status of patients with endometriosis treated with Visanne
- (and 3 more...)
|
3006 |
Female |
18 Years and older (Adult, Senior) |
NCT01595724 |
16108
VS1101 |
DIVA |
May 2012 |
July 2014 |
May 2015 |
May 10, 2012 |
July 10, 2015 |
|
- Many Locations, Belarus
- Many Locations, Egypt
- Many Locations, Jordan
- (and 8 more...)
|
| 127 |
NCT01321840 |
Completed |
Cortical Plasticity in a Complex Intervention for Endometriosis |
|
- Procedure: Specific Autoregulation Therapy (SART)
|
Interventional |
Not Applicable |
- University of Jena
- Technische Universität München
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Brain function
- Reduction of pain
- Pain scores
- (and 3 more...)
|
60 |
Female |
18 Years and older (Adult, Senior) |
NCT01321840 |
Jena-Endo-01 |
|
March 2010 |
December 2012 |
December 2012 |
March 24, 2011 |
January 6, 2017 |
|
- Pain & Autonomics - Integrative Research, Klinik für Psychiatrie und Psychotherapie
Jena, Germany - Frauenklinik der Technischen Universität München
München, Germany
|
| 128 |
NCT02542410 |
Recruiting |
Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study |
|
- Drug: Cabergoline
- Drug: Norethindrone acetate
|
Interventional |
Phase 2 |
- Boston Children’s Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in pain scores
- Changes in functional disability scores
|
14 |
Female |
15 Years to 40 Years (Child, Adult) |
NCT02542410 |
P00018628 |
|
May 2016 |
January 2018 |
March 2018 |
September 7, 2015 |
August 16, 2017 |
|
- Children's Hospital Boston
Boston, Massachusetts, United States
|
| 129 |
NCT00115661 |
Terminated |
Use of Rosiglitazone in the Treatment of Endometriosis |
|
|
Interventional |
Phase 2 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Berlex Foundation
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 28-day visual analog scale diary (one for each day for 4 weeks) at baseline and at conclusion of 6 months
- Short-Form McGill Pain Questionnaire at study entry and at 3 and 6 months
- Physical component summary score of the SF-36 at baseline and at 3 and 6 months
- (and 3 more...)
|
25 |
Female |
18 Years to 45 Years (Adult) |
NCT00115661 |
2004-1013
1K23HD043952-01A2 |
|
July 2005 |
May 2006 |
May 2006 |
June 24, 2005 |
October 17, 2012 |
|
- University of Michigan Health System
Ann Arbor, Michigan, United States
|
| 130 |
NCT02427386 |
Completed |
Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis |
|
- Drug: dynamized estrogen
- Drug: placebo
|
Interventional |
Phase 4 |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- chronic pelvic pain (measured by visual analog scale (VAS-Pain)
- 36-Item Short-Form Health Survey (SF-36)
|
50 |
Female |
18 Years to 45 Years (Adult) |
NCT02427386 |
FMUSP |
|
May 2014 |
February 2016 |
December 2016 |
April 28, 2015 |
February 24, 2017 |
|
|
| 131 |
NCT02437175 |
Active, not recruiting |
Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study |
|
- Dietary Supplement: ENDO 1/ENDO 2
- Dietary Supplement: Placebo
|
Interventional |
Phase 3 |
- Laboratoires Pronutri
- Expert Clinical Services Organization (ECSOR)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Pain (visual analog scale)
- EHP-30 (validated 30-items questionnaire)
- Rescue medication consumption (Number of ibuprofen tablets consumed)
- Safety (Non-serious and serious adverse events (related or not)
|
99 |
Female |
18 Years to 45 Years (Adult) |
NCT02437175 |
Pronutri-IIIa-001 |
|
May 2015 |
December 2018 |
December 2018 |
May 7, 2015 |
April 4, 2018 |
|
- CHU Vésale
Montigny-le-Tilleul, Hainaut, Belgium
|
| 132 |
NCT01921634 |
Recruiting |
Endometriosis and the Appendix - Incidence and Pathologic Analysis |
- Endometriosis of the Appendix
|
- Other: Modified Pathologic Analysis
|
Interventional |
Not Applicable |
- Milton S. Hershey Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
|
- Incidence of Endemetriosis of the Appendix
|
100 |
Female |
18 Years to 51 Years (Adult) |
NCT01921634 |
042383EP |
|
August 2013 |
January 2018 |
January 2018 |
August 13, 2013 |
December 19, 2017 |
|
- Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
|
| 133 |
NCT00437658 |
Completed |
Safety and Efficacy Study of NBI-56418 in Endometriosis |
|
- Drug: NBI-56418
- Drug: depo-subQ provera 104
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Bone mineral density
- Bone mineral density (%Change from baseline)
- Composite pelvic signs and symptoms score
|
252 |
Female |
18 Years to 49 Years (Adult) |
NCT00437658 |
NBI-56418-0603 |
|
November 2006 |
November 2008 |
November 2008 |
February 21, 2007 |
January 8, 2013 |
|
- Site Reference ID/Investigator# 58197
Enterprise, Alabama, United States - Site Reference ID/Investigator# 58510
Glendale, Arizona, United States - Site Reference ID/Investigator# 58208
Phoenix, Arizona, United States - (and 75 more...)
|
| 134 |
NCT00556075 |
Terminated
Has Results |
Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis |
|
- Drug: Proellex 25 mg
- Drug: Placebo
- Drug: Proellex 50 mg
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Difference Between the 50 mg Proellex Group and Placebo Group in the Month 4 Subject Diary Composite Pain Score
- Difference Between the 25 mg and 50 mg Proellex Groups and Placebo Group in the Month 4 Subject Diary Composite Pain Score
- Difference Between Each Treatment Group in the Subject Diary Composite Pain Score at the Monthly Visits
- (and 3 more...)
|
67 |
Female |
18 Years to 48 Years (Adult) |
NCT00556075 |
ZPE-201 |
|
November 2007 |
May 2009 |
July 2009 |
November 9, 2007 |
August 25, 2014 |
August 25, 2014 |
- Advanced Clinical Therapeutics, LLC
Tucson, Arizona, United States - Lynn Institute of the Ozarks
Little Rock, Arkansas, United States - Medical Center for Clinical Research
San Diego, California, United States - (and 14 more...)
|
| 135 |
NCT01402791 |
Completed |
Endometriosis: Sexual Dysfunction and Adaptation Strategies Among Couples |
|
|
Observational |
|
- Centre Hospitalier Universitaire de Nīmes
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Score for the SFQ questionnaire
- Score for the IIEF questionnaire
- Scores for each sub-domain of the SFQ questionnaire
- (and 2 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01402791 |
LOCAL/2011/SD-05
2011-A00564-37 |
DYSEXTRIOSE |
January 2011 |
December 2011 |
December 2011 |
July 26, 2011 |
March 26, 2015 |
|
- Centre Hospitalier Universitaire de Nîmes
Nîmes Cedex 09, Gard, France
|
| 136 |
NCT03352076 |
Recruiting |
Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy |
|
- Drug: Vaginal Danazol
- Drug: Oral Danatrol
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intraperitoneal concentration of Danazol
- Serum Concentration of Danazol
- Concentrations of Danazol in the endometrial tissue outside the Uterus
|
24 |
Female |
18 Years to 42 Years (Adult) |
NCT03352076 |
VML-0501-001 |
|
December 28, 2017 |
May 2018 |
July 2018 |
November 24, 2017 |
January 18, 2018 |
|
- Ospedale L. Sacco - Milan-Obgyn Unit
Milan, Italy
|
| 137 |
NCT02669238 |
Not yet recruiting |
Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis |
|
- Device: Nexplanon®
- Drug: Minidril®/Leeloo®
|
Interventional |
Phase 2
Phase 3 |
- Centre Hospitalier Universitaire de la Réunion
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Global satisfaction
- Pain evaluation
- Daily life impact
- (and 7 more...)
|
160 |
Female |
18 Years to 45 Years (Adult) |
NCT02669238 |
2015/CHU/03 |
END-IMPACT |
June 2017 |
January 2020 |
February 2020 |
February 1, 2016 |
January 18, 2017 |
|
|
| 138 |
NCT00121953 |
Withdrawn |
Effect of Rosiglitazone on Peritoneal Cytokines in Women With Endometriosis |
|
|
Interventional |
Phase 2
Phase 3 |
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Diagnostic
|
- Peritoneal fluid cytokine concentrations
- Cytokine quantification
- Proteomics
- Gene array analyses
|
0 |
Female |
18 Years to 45 Years (Adult) |
NCT00121953 |
2004-1012
1K23HD043952-01A2 |
|
July 2005 |
May 2008 |
May 2008 |
July 21, 2005 |
October 17, 2012 |
|
- University of Michigan Health System
Ann Arbor, Michigan, United States
|
| 139 |
NCT02778919 |
Recruiting |
Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis |
|
- Drug: KLH-2109
- Drug: Placebo
- Drug: Leuprorelin acetate
|
Interventional |
Phase 2 |
- Kissei Pharmaceutical Co., Ltd.
|
Industry |
|
- Change of average Numerical Rating Scale (NRS) score of pelvic pain
- Incidences of adverse events
|
|
Female |
20 Years and older (Adult, Senior) |
NCT02778919 |
KLH1204 |
|
|
March 2019 |
|
May 20, 2016 |
May 23, 2016 |
|
- Tokyo and Other Japanese City, Japan
|
| 140 |
NCT02924493 |
Active, not recruiting |
Dietary Treatment of Endometriosis-related Irritable Bowel Syndrome |
- Endometriosis
- Irritable Bowel Syndrome
- Visceral Syndrome
- Visceral Hypersensitivity
|
- Other: Diet low in fermentable carbohydrates (low FODMAP diet)
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Compliance to the diet measured by a self-administered questionnaire with a percentage scale for every meal consumed
- How manageable the participants experience the diet, measured by semi-quantitative questionnaire designed by the study group
- Identification of intervention group measured by the question: "What group do you think you were assigned to?"
- (and 6 more...)
|
22 |
Female |
18 Years to 50 Years (Adult) |
NCT02924493 |
Diet-in-endometriosis |
|
July 3, 2017 |
December 2017 |
February 2018 |
October 5, 2016 |
October 27, 2017 |
|
- Aarhus University Hospital
Aarhus, Denmark
|
| 141 |
NCT02480647 |
Completed |
Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis |
|
- Drug: Levonorgestrel
- Drug: Etonogestrel
|
Interventional |
Phase 4 |
- University of Campinas, Brazil
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pelvic pain. Pain intensity measure: Self reported pain intensity daily. each item scored 0-10.
- Uterine bleeding
- Cancer antigen 125
|
100 |
Female |
18 Years to 45 Years (Adult) |
NCT02480647 |
44827415200005404 |
|
May 2016 |
August 2017 |
August 2017 |
June 24, 2015 |
August 14, 2017 |
|
- Nelsilene Mota Carvalho
Campinas, São Paulo, Brazil
|
| 142 |
NCT01631981 |
Completed |
PGL2001 Proof of Concept Study in Symptomatic Endometriosis |
|
- Drug: PGL2001 + Primolut-Nor 5
- Drug: Placebo + Primolut-Nor 5
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Non-menstrual pelvic pain.
|
162 |
Female |
18 Years to 45 Years (Adult) |
NCT01631981 |
PGL11-007 |
AMBER |
June 2012 |
October 2013 |
May 2014 |
June 29, 2012 |
June 3, 2014 |
|
- Synexus Magyarország Kft.
Budapest, Hungary - Semmelweis Egyetem II. Szülészeti és Nőgyógyászati Klinika
Budapest, Hungary - Debreceni Egyetem Orvos-es Egeszsegtudomanyi Centrum Szuleszeti es Nogyogyaszati Klinika
Debrecen, Hungary - (and 17 more...)
|
| 143 |
NCT00939861 |
Unknown † |
Laparoscopy Versus Laparotomy for Colorectal Endometriosis |
|
- Procedure: laparoscopy
- Procedure: laparotomy
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluation of dyschesia at 6 months using a visual analogue scale
- Evaluation of gynaecologic symptoms (dysmenorrhea, dyspareunia), digestive symptoms (diarrhea, constipation , intestinal cramps) and general symptoms (asthenia, back pain) at 6 months using visual analogue scale
- Evaluation of quality of life at 6 months using SF-36 questionnaire
- (and 2 more...)
|
52 |
Female |
18 Years to 50 Years (Adult) |
NCT00939861 |
13072009 |
|
January 2006 |
May 2009 |
September 2009 |
July 15, 2009 |
July 15, 2009 |
|
- Tenon Hospital, Departement of Obstetrics and Gynecology
Paris, France
|
| 144 |
NCT01629420 |
Completed |
A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis |
|
|
Interventional |
Phase 2 |
- Kissei Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The severity score of the pelvic pain
|
20 |
Female |
20 Years and older (Adult, Senior) |
NCT01629420 |
KLH1203 |
|
|
|
|
June 27, 2012 |
May 30, 2014 |
|
- Japan
Tokyo and Other Japanese City, Japan
|
| 145 |
NCT02350413 |
Unknown † |
Multicenter Italian Validation of EHP-30 |
- Endometriosis
- Quality of Life
|
- Other: The Endometriosis Health Profile EPH-30
|
Observational |
|
- University of Cagliari
- University of Siena
- University of Foggia
- (and 3 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
200 |
Female |
18 Years to 45 Years (Adult) |
NCT02350413 |
ENDOCA1415 |
|
May 2014 |
September 2016 |
October 2016 |
January 29, 2015 |
November 24, 2015 |
|
- University of Cagliari,Obstetrics and Gynecological Department,
Monserrato, Cagliari, Italy
|
| 146 |
NCT01630252 |
Completed |
PGL5001 Proof of Concept Study in Inflammatory Endometriosis |
|
- Drug: PGL5001
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline to end of treatment in the number and percentage of red lesions (and/or inflammatory lesions), based on total number of red and black lesions.
|
24 |
Female |
18 Years and older (Adult, Senior) |
NCT01630252 |
PGL11-021 |
JADE |
June 2012 |
September 2013 |
October 2013 |
June 28, 2012 |
June 3, 2014 |
|
- Prywatna Klinika Połozniczo-Ginekologiczna Sp z o.o.
Bialystok, Poland
|
| 147 |
NCT01732432 |
Withdrawn |
Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) |
- Endometrioid Carcinoma
- Clear Cell Carcinoma
- Endometriosis
|
|
Observational |
|
- University Hospital, Basel, Switzerland
|
Other |
- Time Perspective: Retrospective
|
- incidence and clinical outcome of endometriosis-associated ovarian carcinomas
|
0 |
Female |
30 Years to 85 Years (Adult, Senior) |
NCT01732432 |
210/12 |
EAOC |
October 2012 |
August 2013 |
December 2013 |
November 22, 2012 |
April 1, 2015 |
|
|
| 148 |
NCT01697111 |
Completed |
Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis |
|
- Drug: EE20/DRSP(BAY86-5300)
- Drug: Placebo
- Drug: Dienogest
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change of pelvic pain from baseline period (8 weeks before start of treatment) to period of treatment (weeks 17-24)
- Pelvic pain during menstrual or withdrawal bleeding period (except for dyspareunia and defecation pain)
- Pelvic pain during non-menstrual period and non-withdrawal bleeding period (except for dyspareunia and defecation pain)
- (and 5 more...)
|
312 |
Female |
20 Years and older (Adult, Senior) |
NCT01697111 |
15457 |
|
October 2012 |
March 2014 |
December 2014 |
October 2, 2012 |
February 18, 2016 |
|
- Anjo, Aichi, Japan
- Ichinomiya, Aichi, Japan
- Nagoya, Aichi, Japan
- (and 29 more...)
|
| 149 |
NCT02761382 |
Recruiting |
Psychological Pain Treatment in Endometriosis |
- Endometriosis
- Pelvic Pain
- Chronic Pain
|
- Other: Mindfulness-based psychological treatment
- Other: Non-specific psychological treatment
|
Interventional |
Not Applicable |
- University of Aarhus
- Aarhus University Hospital
- TrygFonden, Denmark
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pelvic pain measured on Numeric Rating Scale
- Quality of life measured by the Endometriosis Health Profile 30 questionnaire
- Endometriosis related symptoms measured on Numeric Rating Scale
- (and 3 more...)
|
100 |
Female |
18 Years to 47 Years (Adult) |
NCT02761382 |
AUENDO |
|
March 2016 |
June 2018 |
June 2019 |
May 4, 2016 |
June 20, 2017 |
|
- Aarhus University Hospital, Department of Obstetrics and Gynecology
Aarhus N, Denmark - Copenhagen University Hospital, Department of Gynaecology
Copenhagen, Denmark
|
| 150 |
NCT01533532 |
Completed |
A Randomized, Placebo-controlled, Double-blind Study of KLH-2109 in Patients With Endometriosis (2) |
|
- Drug: KLH-2109
- Drug: placebo
|
Interventional |
Phase 2 |
- Kissei Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The severity score of the pelvic pain
|
100 |
Female |
20 Years and older (Adult, Senior) |
NCT01533532 |
KLH1202 |
|
|
|
|
February 15, 2012 |
May 30, 2014 |
|
- Japan
Tokyo and Other Japanese City, Japan
|
Create an RSS feed from your search for:
Download the search results for: